Boston Scientific shares fall 2.22% but outperform sector in market downturn
Updated
Updated · MarketWatch · Apr 29
Boston Scientific shares fall 2.22% but outperform sector in market downturn
10 articles · Updated · MarketWatch · Apr 29
Boston Scientific closed at $57.15 on Wednesday, marking its fourth consecutive day of losses and trading 47.81% below its 52-week high.
Despite the decline, Boston Scientific outperformed major competitors like Abbott Laboratories, Medtronic, and Stryker, which saw larger percentage drops.
The broader market also fell, with the S&P 500 down 0.04% and the Dow Jones down 0.57%, while Boston Scientific's trading volume exceeded its 50-day average.
Why are analysts optimistic about Boston Scientific despite its falling stock and lowered guidance?
How is the MedTech industry's shift to outpatient surgery centers affecting Boston Scientific's strategy?
Could securities-fraud lawsuits derail Boston Scientific’s recovery more than the market currently expects?
How will the high-stakes Penumbra acquisition reshape the neurovascular market and Boston Scientific’s future?
Can Boston Scientific's FARAPULSE system win the PFA market war despite growing competition?